Global Systemic Lupus Erythematosus Market by Drug Type (Antimalarial Drugs, B-Cell Modulators, Biologics), Mode of Delivery (Intravenous, Oral, Subcutaneous) - Forecast 2024-2030- Product Image

Sale

Global Systemic Lupus Erythematosus Market by Drug Type (Antimalarial Drugs, B-Cell Modulators, Biologics), Mode of Delivery (Intravenous, Oral, Subcutaneous) - Forecast 2024-2030

Report
182 Pages
March 2024
Region: Global
360iResearch™
ID: 5666463

UP TO €846EUR$875USD£717GBP OFF until Dec 31^st 2024

The Systemic Lupus Erythematosus Market size was estimated at USD 2.04 billion in 2023, USD 2.24 billion in 2024, and is expected to grow at a CAGR of 10.54% to reach USD 4.12 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Systemic Lupus Erythematosus Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Systemic Lupus Erythematosus Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Systemic Lupus Erythematosus Market, highlighting leading vendors and their innovative profiles. These include Abbvie, Inc., Amgen Inc., AstraZeneca PLC, Aurinia Pharmaceuticals Inc., bioMérieux SA, Boston Pharmaceuticals Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline PLC, Hoffmann-LA-Roche Ltd., ImmuPharma PLC, Mylan N.V., Novartis AG, Pfizer, Inc., and Xencor, Inc.

Market Segmentation & Coverage

This research report categorizes the Systemic Lupus Erythematosus Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Antimalarial Drugs
  - Chloroquine
  - Hydrochloroquine
- B-Cell Modulators
- Biologics
  - Approved Biologics for Treating SLE
    - B-Cell Targeted Therapy
    - Blys-Blockers (Belimumab)
  - Biologics Used Off-Label
- Cytotoxic & Immunosuppressive Drugs
  - Cyclophosphamide
  - Cyclosporine
  - Methotrexate
  - Mycophenolate Mofetil or Tacrolimus
- Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators
- Non-Steroidal Anti-Inflammatory Drugs
- Pro-Inflammatory & Cytokine Inhibitors
Mode of Delivery
- Intravenous
- Oral
- Subcutaneous
- Topical

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Systemic Lupus Erythematosus Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Systemic Lupus Erythematosus Market?
What are the technology trends and regulatory frameworks in the Systemic Lupus Erythematosus Market?
What is the market share of the leading vendors in the Systemic Lupus Erythematosus Market?
Which modes and strategic moves are suitable for entering the Systemic Lupus Erythematosus Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Systemic Lupus Erythematosus Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of systemic lupus erythematosus worldwide
5.1.1.2. Rising awareness of inflammatory autoimmune diseases and treatment
5.1.1.3. Improvement in healthcare infrastructure and lupus treatment clinics
5.1.2. Restraints
5.1.2.1. High cost of treatment and lack of infrastructure in low-income countries
5.1.3. Opportunities
5.1.3.1. Significant funding and investment for lupus research activities
5.1.3.2. Advancement in treatment technologie and launch of new products
5.1.4. Challenges
5.1.4.1. Complications in treatment and other difficulties in managing SLE
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Systemic Lupus Erythematosus Market, by Drug Type

6.1. Introduction
6.2. Antimalarial Drugs
6.3.1. Chloroquine
6.3.2. Hydrochloroquine
6.3. B-Cell Modulators
6.4. Biologics
6.5.1. Approved Biologics for Treating SLE
6.5.2.1. B-Cell Targeted Therapy
6.5.2.2. Blys-Blockers (Belimumab)
6.5.2. Biologics Used Off-Label
6.5. Cytotoxic & Immunosuppressive Drugs
6.6.1. Cyclophosphamide
6.6.2. Cyclosporine
6.6.3. Methotrexate
6.6.4. Mycophenolate Mofetil or Tacrolimus
6.6. Immunosuppressive & Cytotoxic Drugs & T-Cell Modulators
6.7. Non-Steroidal Anti-Inflammatory Drugs
6.8. Pro-Inflammatory & Cytokine Inhibitors

7. Systemic Lupus Erythematosus Market, by Mode of Delivery

7.1. Introduction
7.2. Intravenous
7.3. Oral
7.4. Subcutaneous
7.5. Topical

8. Americas Systemic Lupus Erythematosus Market

8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Systemic Lupus Erythematosus Market

9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam

10. Europe, Middle East & Africa Systemic Lupus Erythematosus Market

10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom

11. Competitive Landscape

11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player

12. Competitive Portfolio

12.1. Key Company Profiles
12.1.1. Abbvie, Inc.
12.1.2. Amgen Inc.
12.1.3. AstraZeneca PLC
12.1.4. Aurinia Pharmaceuticals Inc.
12.1.5. bioMérieux SA
12.1.6. Boston Pharmaceuticals Inc.
12.1.7. Bristol-Myers Squibb Company
12.1.8. Eli Lilly and Company
12.1.9. GlaxoSmithKline PLC
12.1.10. Hoffmann-LA-Roche Ltd.
12.1.11. ImmuPharma PLC
12.1.12. Mylan N.V.
12.1.13. Novartis AG
12.1.14. Pfizer, Inc.
12.1.15. Xencor, Inc.
12.2. Key Product Portfolio

13. Appendix

13.1. Discussion Guide
13.2. License & Pricing

List of Figures

FIGURE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET RESEARCH PROCESS
FIGURE 2. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2023 VS 2030
FIGURE 3. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET DYNAMICS
FIGURE 7. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2030 (%)
FIGURE 10. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 20. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 6. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 8. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY HYDROCHLOROQUINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 13. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 15. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY B-CELL TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BLYS-BLOCKERS (BELIMUMAB), BY REGION, 2018-2030 (USD MILLION)
TABLE 17. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS USED OFF-LABEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 20. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOPHOSPHAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MYCOPHENOLATE MOFETIL OR TACROLIMUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY IMMUNOSUPPRESSIVE & CYTOTOXIC DRUGS & T-CELL MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY PRO-INFLAMMATORY & CYTOKINE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 28. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 41. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 42. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 43. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 44. ARGENTINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 46. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 47. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 48. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 49. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 50. BRAZIL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 51. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 52. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 53. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 54. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 55. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 56. CANADA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 57. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 59. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 60. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 61. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 62. MEXICO SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 65. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 66. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 67. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 68. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 69. UNITED STATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 72. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 73. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 74. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 75. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 76. ASIA-PACIFIC SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 78. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 79. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 80. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 81. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 82. AUSTRALIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 83. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 84. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 85. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 86. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 87. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 88. CHINA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 89. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 90. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 91. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 92. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 93. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 94. INDIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 96. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 97. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 98. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 99. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 100. INDONESIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 101. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 102. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 103. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 104. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 105. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 106. JAPAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 108. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 109. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 110. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 111. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 112. MALAYSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 115. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 116. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 117. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 118. PHILIPPINES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 120. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 121. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 122. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 123. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 124. SINGAPORE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 126. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 127. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 128. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 129. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 130. SOUTH KOREA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 132. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 133. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 134. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 135. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 136. TAIWAN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 137. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 139. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 140. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 141. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 142. THAILAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 144. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 145. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 146. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 147. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 148. VIETNAM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 156. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 157. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 158. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 159. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 160. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 161. DENMARK SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 162. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 163. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 164. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 165. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 166. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 167. EGYPT SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 168. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 169. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 170. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 171. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 172. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 173. FINLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 174. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 175. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 176. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 177. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 178. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 179. FRANCE SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 180. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 181. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 182. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 184. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 185. GERMANY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 187. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 188. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 189. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 190. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 191. ISRAEL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 192. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 193. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 194. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 195. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 196. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 197. ITALY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 202. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 203. NETHERLANDS SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 205. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 206. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 207. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 208. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 209. NIGERIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 210. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 211. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 212. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 213. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 214. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 215. NORWAY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 216. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 217. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 218. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 219. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 220. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 221. POLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 222. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 223. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 224. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 225. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 226. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 227. QATAR SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 229. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 230. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 231. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 232. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 233. RUSSIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 236. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 237. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 238. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 239. SAUDI ARABIA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 244. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 246. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 247. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 248. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 249. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 250. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 251. SPAIN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 253. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 254. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 255. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 256. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 257. SWEDEN SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 259. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 260. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 264. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 265. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 266. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 267. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 268. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 269. TURKEY SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 275. UNITED ARAB EMIRATES SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 277. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY ANTIMALARIAL DRUGS, 2018-2030 (USD MILLION)
TABLE 278. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 279. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY APPROVED BIOLOGICS FOR TREATING SLE, 2018-2030 (USD MILLION)
TABLE 280. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY CYTOTOXIC & IMMUNOSUPPRESSIVE DRUGS, 2018-2030 (USD MILLION)
TABLE 281. UNITED KINGDOM SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SIZE, BY MODE OF DELIVERY, 2018-2030 (USD MILLION)
TABLE 282. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 283. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 284. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET LICENSE & PRICING

Companies Mentioned

Abbvie, Inc.
Amgen Inc.
AstraZeneca PLC
Aurinia Pharmaceuticals Inc.
bioMérieux SA
Boston Pharmaceuticals Inc.
Bristol-Myers Squibb Company
Eli Lilly and Company
GlaxoSmithKline PLC
Hoffmann-LA-Roche Ltd.
ImmuPharma PLC
Mylan N.V.
Novartis AG
Pfizer, Inc.
Xencor, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	182
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 2.24 Billion
Forecasted Market Value ( USD ) by 2030	$ 4.12 Billion
Compound Annual Growth Rate	10.5%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3263EUR$3,374USD£2,763GBP €3625EUR$3,749USD£3,070GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4133EUR$4,274USD£3,500GBP €4593EUR$4,749USD£3,889GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5004EUR$5,174USD£4,238GBP €5560EUR$5,749USD£4,708GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5874EUR$6,074USD£4,975GBP €6527EUR$6,749USD£5,527GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7615EUR$7,874USD£6,449GBP €8461EUR$8,749USD£7,165GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Systemic Lupus Erythematosus (SLE) Drugs Market by Drug Class (Antimalarials Drugs, Non-Steroidal Anti-Inflammatory Drugs (NSAIDS), Cytotoxic and Immunosuppressive Drugs, Biologics, and Others), Mode of Delivery (Intravenous, Subcutaneous, Oral), and Region 2024-2032

Systemic Lupus Erythematosus Treatment Global Market Report 2024

Systemic Lupus Erythematosus Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

Systemic Lupus Erythematosus (Sle) Drugs - Global Strategic Business Report

Systemic Lupus Erythematosus Drug Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type